Immunic (IMUX)
(Delayed Data from NSDQ)
$1.28 USD
+0.03 (1.99%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.29 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 181 - 200 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Dial in on Jun. 12 to Discover How IMU-838 Can Tackle Multiple Sclerosis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Dial In Today at 12pm ET to Figure Out IMU-838''s Game Plan
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM, $59 PT: Target Selectivity Creates Best-in-Class
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Dial In on Jun. 4 at 12pm ET to Figure Out IMU-838''s Game Plan
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our COVID-19 Expert Call with Dr. Michael Millis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our COVID-19 Expert Call Today at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
R-D Day Event Showcases COVID-19 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our 3-Part Call Series Starting May 29
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our 3-Part Call Series Starting May 29
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y